<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516525</url>
  </required_header>
  <id_info>
    <org_study_id>1/AGB</org_study_id>
    <nct_id>NCT04516525</nct_id>
  </id_info>
  <brief_title>The Impact of CRT on Renal Function</brief_title>
  <official_title>Assessment of the Impact of Resynchronization Therapy on Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rzeszow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rzeszow</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is observational, prospective, including patients undergoing CRT-D / CRT-P&#xD;
      implantation in the department of cardiology. In the current project, the researchers assumed&#xD;
      that the improvement in cardiac function obtained in patients qualified according to the ESC&#xD;
      / PTK guidelines for resynchronization therapy may improve renal function in a prospective&#xD;
      12-month follow-up. In addition, it is planned to take into account the possibility of&#xD;
      temporary deterioration of kidney function, which may occur immediately after implantation of&#xD;
      the resynchronization device due to the nephrotoxic effect of the contrast agent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2016</start_date>
  <completion_date type="Actual">August 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Evaluation of changes renal function: 48 hours, one month and one year after cardiac resynchronization therapy device implantation procedure.</measure>
    <time_frame>1 year for each patient in the study</time_frame>
    <description>Assessment of the number of patients with with chronic type 2 cardio-renal syndrome with improvement or deterioration renal function assessed by blood and urine biomarkers within the first 48 hours, one month and one year after CRT implantation.</description>
  </primary_outcome>
  <enrollment type="Actual">74</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Chronic Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cardiac resynchronisation therapy (CRT) implantation</intervention_name>
    <description>In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urina&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with heart failure who had met the criteria for CRT implantation according&#xD;
        to European Society of Cardiology guidelines for the treatment of heart failure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult patients with heart failure who had met the criteria for CRT implantation according&#xD;
        to European Society of Cardiology guidelines for the treatment of heart failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no written consent to participate in the study&#xD;
&#xD;
          -  no indications for CR implantation&#xD;
&#xD;
          -  current infection&#xD;
&#xD;
          -  children&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <reference>
    <citation>Gala-Błądzińska A, Romanek J, Mazur D, Stepek T, Braun M, Szafarz P, Chlebuś M, Przybylski A. Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2. Cardiol Res Pract. 2020 Mar 21;2020:2727108. doi: 10.1155/2020/2727108. eCollection 2020.</citation>
    <PMID>32274209</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 15, 2020</last_update_submitted>
  <last_update_submitted_qc>August 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rzeszow</investigator_affiliation>
    <investigator_full_name>Agnieszka Gala-Bladzinska</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic cardio-renal syndrome biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

